Surgical & Chemical Menopause: Symptoms, HRT & Long-Term Health

A comprehensive patient and clinician guide to medically induced menopause — covering onset, management, HRT, bone health, cardiovascular risk, fertility, and psychological wellbeing.

What Is Medically Induced Menopause?

Menopause is not always a natural, gradual transition. For a significant number of women, menopause is medically induced — a process known clinically as iatrogenic menopause. This can happen through surgery, medication, chemotherapy, or radiotherapy. The result in all cases is a reduction in oestrogen and progesterone (and often testosterone) — but the onset, severity, reversibility, and management can differ considerably depending on the cause.

There are two main categories: surgical menopause, caused by the removal of the ovaries, and chemical menopause, caused by drugs or treatments that suppress or damage ovarian function. Both require careful, individualised management — not just for immediate symptoms, but for long-term bone, cardiovascular, cognitive, and psychological health.

Surgical Menopause

What Is Surgical Menopause?

Surgical menopause occurs when both ovaries are removed — a procedure called a bilateral oophorectomy, which is often carried out at the same time as a hysterectomy (removal of the womb). Because the ovaries are the primary source of oestrogen and progesterone, their removal triggers an immediate and complete menopause, regardless of the woman’s age. Testosterone is also produced in the adrenal glands and so there is not the precipitous decline seen with oestrogen and progesterone.

This is fundamentally different from natural menopause, which happens gradually as ovarian function declines over years. With surgical menopause, hormone levels fall sharply within hours of the procedure. For younger women — particularly those who have not yet reached the average age of natural menopause (around 51 in the UK) — this abrupt hormonal shift can be especially challenging.

Clinical note: Because of the sudden nature of hormonal withdrawal, symptoms of surgical menopause are frequently more severe and more immediate than those experienced during natural menopause. Women should be fully prepared for this before the procedure takes place.

Why Is Surgical Menopause Performed?

Surgical menopause is typically considered when other treatments have not provided adequate relief, or when the ovaries need to be removed for medical reasons. Common indications include:

• Endometriosis — severe or treatment-resistant disease
• Ovarian cysts or confirmed/suspected ovarian cancer
• Preventative surgery in high-risk individuals — for example, those carrying the BRCA1 or BRCA2 gene mutations
• Chronic or intractable pelvic pain
• Severe Premenstrual Dysphoric Disorder (PMDD)
• Cancer of the endometrium (lining of the womb) or cervix, where surgery forms part of treatment

Because surgical menopause is irreversible, it should only be pursued after a thorough discussion with your specialist about the benefits, risks, and all available alternatives. This is a major, life-changing decision — and informed consent is not just a formality, it is essential.

Symptoms of Surgical Menopause

The symptoms of surgical menopause are the same as those of natural menopause, but they tend to arrive more suddenly and with greater intensity. They may begin within days of surgery and can include:

• Hot flushes and night sweats
• Sleep disturbance and fatigue
• Mood changes, anxiety, and low mood
• Brain fog and difficulty concentrating
• Vaginal dryness and discomfort during sex
• Reduced libido
• Joint pain and muscle aches
• Skin and hair changes
• Palpitations

Younger women undergoing surgical menopause — those in their 20s, 30s, or 40s — often find symptoms particularly difficult to manage, partly because their bodies were not expecting this hormonal shift and partly because they may receive inadequate hormone replacement doses for their age group.

How to Prepare for Surgical Menopause

Preparation before surgery can make a significant difference to how well women manage both the immediate aftermath and the longer-term impact. Proactive planning is far more effective than reactive symptom management.

1. Understand your individual risk profile

Your doctor should help you assess the specific risks that apply to you before proceeding. These include:

• Your age at the time of surgery
• Your current bone health — a DEXA scan to measure bone density may be appropriate
• Your cardiovascular risk profile — blood pressure, BMI, and lipid levels
• Your family history of heart disease, osteoporosis, or cancer
• Your fertility wishes — if you have not completed your family, egg harvesting (fertility preservation) before surgery may be an option worth discussing

2. Discuss hormone replacement therapy (HRT / MHT) in advance

Menopausal Hormone Therapy (MHT — also commonly called HRT) is usually the first-line treatment following surgical menopause, unless there is a specific medical reason it cannot be used. Ideally, this conversation should happen before surgery, not after.

Key questions to address with your specialist include: When will HRT begin (often immediately post-operatively)? Which type — oestrogen-only, or combined? And which route of administration — transdermal patches or gels are generally preferred as they carry a lower risk of blood clots compared to oral preparations.

3. Psychological preparation

The sudden loss of ovarian hormones does not only affect physical health — it can have a profound impact on mood, emotional wellbeing, identity, and body image. Many women describe feeling unprepared for the emotional dimension of surgical menopause. Discussing this in advance, and having appropriate support in place, can make a meaningful difference to recovery and adjustment.

Questions to Ask Your Consultant Before Surgical Menopause

It is your right to ask clear, direct questions before consenting to this procedure. You should feel fully informed. Consider asking:

• Will both ovaries be removed — and why is that necessary in my case?
• Are there alternative treatments I have not yet tried?
• Should I consider egg harvesting before surgery if I wish to preserve my fertility?
• What symptoms should I expect, and how quickly will they arrive?
• What is your plan for starting MHT — and when?
• What are the long-term risks to my bone, heart, and brain health?
• Will testosterone be considered if I experience low libido?
• How might this affect my sexual function and vaginal health?
• What non-hormonal options exist if I cannot take MHT?

Post-Operative Care and Long-Term Management

Management of surgical menopause extends well beyond the immediate post-operative period. Women should expect ongoing monitoring and support in several areas:

Hormonal treatment

MHT is the cornerstone of post-surgical menopause management for most women. Younger women who have undergone surgical menopause before the natural age of menopause typically require higher doses of oestrogen than older women going through natural menopause, to adequately replace what their body would otherwise have been producing. The type and dose should be reviewed regularly.

Bone health

Oestrogen plays a critical role in maintaining bone density. Without it, bone loss accelerates — increasing the risk of osteoporosis and fractures. Women who have undergone surgical menopause should ensure adequate calcium and vitamin D intake, engage in regular weight-bearing exercise, and have bone density monitoring at appropriate intervals.

Cardiovascular health

Oestrogen has a protective effect on the cardiovascular system. Early menopause — particularly surgical menopause before the age of 45 — is associated with an increased risk of heart disease. Cardiovascular risk factors such as blood pressure, cholesterol, and BMI should be monitored and managed proactively.

Cognitive wellbeing

There is growing evidence that oestrogen also supports cognitive function and brain health. Women who experience early surgical menopause may face a higher risk of cognitive decline if adequate hormonal support is not provided. This is an area of active clinical research, and it underlines the importance of not delaying or under-treating hormonal replacement.

Sexual wellbeing

Vaginal dryness, discomfort during sex, and reduced libido are common following surgical menopause. Local (topical) oestrogen applied directly to the vaginal area can be highly effective for genitourinary symptoms and can be used safely alongside systemic HRT. Where low libido persists despite adequate oestrogen replacement, testosterone therapy may be considered — it has a growing evidence base for this indication in women. However, it must always be remembered that the relationship between libido and testosterone is not a linear one, meaning that if testosterone is prescribed, there is not a guaranteed response, as psychosexual issues play a significant role in libido.

Chemical Menopause

What Is Chemical Menopause?

Chemical menopause is a medically induced menopause caused by treatments that suppress or damage the ovaries. It can arise in two distinct ways: through medications that deliberately suppress ovarian function for therapeutic purposes, or as a side effect of cancer treatments such as chemotherapy and radiotherapy.

Medication-induced chemical menopause

The most common medications used to induce chemical menopause are GnRH analogues — a class of drugs that includes goserelin (Zoladex) and leuprorelin. These drugs work by suppressing the signals that trigger oestrogen production, effectively ‘switching off’ the ovaries in a controlled, reversible way. They are given as injections, typically every four weeks or every three months.

Common reasons for prescribing GnRH analogues include: endometriosis, uterine fibroids, hormone-sensitive cancers, certain fertility treatment pathways, and — importantly — as a diagnostic ‘trial run’ to assess whether surgical menopause might relieve a patient’s symptoms before committing to irreversible surgery. This is a valuable, though often underused, tool in the clinical pathway.

Chemotherapy-induced menopause

Chemotherapy drugs work by targeting rapidly dividing cells — including cancer cells, but also the cells within the ovaries. This can lead to reduced or suppressed ovarian function, either temporarily or permanently, depending on the drugs used, the doses, and the woman’s age. Chemotherapy-induced menopause is used in the treatment of breast cancer, gynaecological cancers, blood cancers, and others. The likelihood of ovarian recovery after chemotherapy is not always predictable.

Radiotherapy-induced menopause

Radiotherapy directed at the pelvis, abdomen, brain, or areas affecting the ovaries (including treatment for conditions such as leukaemia or Hodgkin’s disease) can damage ovarian function. Unlike medication-induced chemical menopause, ovarian recovery after radiotherapy is not guaranteed — while spontaneous recovery is sometimes possible, it cannot be predicted. This has important implications for fertility, and egg or embryo harvesting before radiotherapy should be discussed where appropriate.

Key distinction: Unlike surgical menopause, medication-induced chemical menopause is reversible — ovarian function typically returns when the drug is stopped. However, menopause induced by chemotherapy or radiotherapy may be permanent, and women should be clearly informed of this possibility before treatment begins.

Symptoms of Chemical Menopause

The symptoms of chemical menopause closely mirror those of natural or surgical menopause, and include:

• Hot flushes and night sweats
• Mood changes, anxiety, and low mood
• Fatigue and sleep disruption
• Vaginal dryness
• Reduced libido
• Brain fog and difficulty concentrating
• Joint pain

Symptoms during medication-induced chemical menopause (e.g. with GnRH analogues) often begin within a few weeks of starting treatment, as the suppression of oestrogen takes effect. The gradual nature of this onset, compared to surgical menopause, can be slightly more manageable — though for some women, symptoms are still significant.

How to Prepare for Chemical Menopause

1. Understand the purpose, duration, and reversibility

Before starting treatment, make sure you understand clearly: Is this short-term (for example, a 3–6 month trial) or longer? Is it being used as a diagnostic tool before considering surgery, or as part of cancer treatment? Is it likely to be reversible? For medication-induced chemical menopause, ovarian function will generally return after stopping the drug. For chemo- or radiotherapy-induced menopause, this cannot always be assumed.

2. Ask about ‘add-back’ therapy

When GnRH analogues are prescribed, low-dose MHT is frequently prescribed alongside them — a strategy known as ‘add-back therapy.’ This reduces the menopausal side effects of the treatment without significantly compromising its therapeutic effectiveness. If you are prescribed a GnRH analogue and are not offered add-back therapy, it is entirely reasonable to ask your specialist about it.

3. Baseline health checks

Before starting chemical menopause — particularly if it is likely to be prolonged — baseline checks should include bone density assessment, cardiovascular risk evaluation, and a mental health baseline. These provide a benchmark for monitoring during and after treatment.

Questions to Ask Your Consultant Before Chemical Menopause

• How long will I be on this treatment — and is there an end date?
• What side effects should I expect, and when?
• Will I receive add-back hormone therapy to manage symptoms?
• How will this affect my bone density during and after treatment?
• Will my periods and fertility return after treatment stops?
• Is this a diagnostic trial before surgery, or a definitive treatment?
• If I am having chemo or radiotherapy, what are the chances of permanent ovarian damage?
• Should I consider fertility preservation (egg or embryo freezing) before starting?

Post-Treatment Considerations: Chemical Menopause

Symptom monitoring

During chemical menopause — particularly with GnRH analogues — symptoms should be actively monitored and managed. If add-back therapy is not sufficient to control symptoms, the formulation or dose may need to be reviewed. It is not acceptable for women to simply ‘put up with’ severe menopausal symptoms during treatment.

Bone health during prolonged treatment

Even temporary suppression of oestrogen can have a meaningful effect on bone density. For treatments lasting more than six months, bone density monitoring may be appropriate. Ensuring adequate calcium and vitamin D intake throughout treatment is important for all women.

Return of ovarian function

For medication-induced chemical menopause, periods and fertility will generally return within a few months of stopping treatment. However, this is not universally the case — women should not assume fertility has returned and should discuss contraception with their doctor if pregnancy is not desired. For those who have had chemotherapy or radiotherapy, the return of ovarian function is not guaranteed, and appropriate discussion and planning should form part of the initial treatment conversation.

Surgical vs Chemical Menopause: At a Glance

The table below summarises the key differences between surgical and chemical menopause to help patients and clinicians navigate treatment planning and expectations.

Long-Term Health Considerations

Both surgical and chemical menopause — particularly when they occur before the natural age of menopause — carry long-term health implications that extend far beyond symptom management. Care should address the following:

Bone Health and Osteoporosis

Oestrogen is essential for maintaining bone mineral density. When oestrogen levels fall — whether through surgery, medication, or cancer treatment — bone resorption accelerates. Women who experience early menopause (before age 45) face a significantly elevated lifetime risk of osteoporosis and fragility fractures. Adequate MHT, calcium, vitamin D, and regular weight-bearing exercise are all components of effective bone protection.

Cardiovascular Health

The protective effect of oestrogen on the cardiovascular system is well established. Premature or early menopause — especially surgical menopause before the age of 45 — is associated with increased rates of cardiovascular disease, including coronary artery disease and stroke. Timely and appropriate MHT, maintained at minimum until the average age of natural menopause, is an important part of managing this risk.

Cognitive Health and Brain Ageing

Emerging research suggests that oestrogen plays a neuroprotective role. Women who undergo early menopause — particularly without adequate hormonal replacement — may face a higher risk of cognitive decline over time. While this area of research is still evolving, it provides further support for the use of appropriate MHT in younger women following medically induced menopause.

Mental Health and Psychological Wellbeing

The psychological impact of medically induced menopause is often underestimated. Whether linked to a cancer diagnosis, the treatment of a chronic condition, or preventative surgery, women may experience grief, a changed sense of identity, anxiety, low mood, and relationship strain. These experiences are valid and deserve clinical attention — not just reassurance. Referral for psychological support, including Cognitive Behavioural Therapy (CBT), should be considered where appropriate, alongside hormonal management.

Sexual Health

Both surgical and chemical menopause can significantly affect sexual wellbeing — through vaginal dryness and discomfort, reduced libido, and changes in sexual response. These symptoms are treatable. Local oestrogen, lubricants, and — where clinically appropriate — testosterone therapy can all play a role. Women should be encouraged to raise these concerns with their healthcare team rather than accepting them as inevitable.

Fertility and Egg Harvesting

For women of reproductive age who have not yet completed their family, medically induced menopause carries significant implications for fertility. This conversation must happen before treatment begins — not after.

• Surgical menopause is permanent: fertility is lost when the ovaries are removed. Women who wish to preserve the possibility of future pregnancy should discuss egg or embryo freezing with a fertility specialist before the procedure.
• Medication-induced chemical menopause is generally reversible, and fertility usually returns after treatment stops. However, this cannot be assumed, and specialist advice should be sought.
• Chemotherapy and radiotherapy may cause permanent damage to the ovaries, particularly at higher doses. The likelihood of ovarian recovery depends on the treatment regimen, age, and individual factors. Fertility preservation should be offered as a standard part of the pre-treatment conversation for any woman of reproductive age.

If you are of reproductive age and facing surgical or chemical menopause as part of your treatment, ask your specialist team about fertility preservation options before treatment begins. This conversation is time-sensitive, as egg or embryo harvesting must be completed before the procedure or treatment starts.

Clinical Summary: Individualised, Proactive Care

Both surgical and chemical menopause demand an individualised, proactive approach. The following principles should guide management:

• Surgical menopause requires long-term planning, usually immediate MHT, and ongoing monitoring of bone, cardiovascular, and cognitive health — potentially for decades.
• Chemical menopause — depending on its cause — may be temporary and reversible (medication-induced) or potentially permanent (chemo- or radiotherapy-related). The treatment approach should reflect this.
• In all cases, care must extend beyond symptom management to include the full picture of long-term health: bone density, cardiovascular risk, cognitive wellbeing, mental health, sexual health, and fertility.
• Women facing medically induced menopause frequently report feeling underprepared. As clinicians and healthcare professionals, our responsibility is not merely to treat symptoms, but to ensure women are fully informed, actively involved in their care, and adequately supported at every stage.

TMC Health provides specialist support for women navigating all forms of menopause — including surgical, chemical, and cancer-related menopause. Our clinicians take a whole-person approach, combining evidence-based hormonal management with psychological support, long-term health monitoring, and personalised care planning.

Frequently Asked Questions

Is surgical menopause the same as natural menopause?

No. Although the symptoms are similar, surgical menopause happens immediately following the removal of the ovaries, rather than gradually over several years. This means symptoms can be more sudden and more severe. Younger women who undergo surgical menopause also face distinct long-term health risks — particularly around bone, cardiovascular, and cognitive health — that require proactive management.

Will I need HRT after surgical menopause?

For most women, yes. MHT (Menopausal Hormone Therapy — also called HRT) is usually the recommended first-line treatment following surgical menopause, unless there is a specific contraindication. Younger women typically require higher doses than those going through natural menopause. The decision about type and dose should be made on an individual basis, ideally discussed with a menopause specialist.

Is chemical menopause permanent?

It depends on the cause. Medication-induced chemical menopause (using GnRH analogues) is reversible — the ovaries typically resume function once treatment stops. However, menopause caused by chemotherapy or radiotherapy may be permanent, and the likelihood of ovarian recovery is not always predictable. This should be discussed clearly with your oncology team before treatment begins.

Can I get pregnant after chemical menopause?

After medication-induced chemical menopause, fertility usually returns once treatment has stopped. After chemotherapy or radiotherapy, this is less certain and depends on the specific treatment and your individual circumstances. If fertility preservation is important to you, discuss egg or embryo harvesting before treatment begins — this is time-sensitive.

What is ‘add-back therapy’?

Add-back therapy refers to the use of low-dose MHT alongside GnRH analogue treatment, to reduce the menopausal side effects that these drugs cause. It is widely used and does not generally reduce the effectiveness of the primary treatment. If you have been prescribed a GnRH analogue without add-back therapy and are struggling with symptoms, it is entirely reasonable to ask your specialist about this option.

What should I do if I feel underprepared for menopause after my treatment?

You are not alone in this experience — many women report feeling underprepared for the hormonal changes that follow surgery or medical treatment. It is never too late to seek specialist support. A menopause specialist can review your hormonal management, address long-term health risks, and connect you with the right support for both physical and psychological wellbeing.

About TMC UK

TMC provides specialist, evidence-based menopause care across multiple UK clinics and online. Our menopause-trained clinicians offer:

• Comprehensive symptom assessment
• Individualised MHT prescribing
• Complex case management
• Second opinions
• Holistic support for all aspects of hormonal health

We believe every woman deserves access to high-quality, personalised menopause care based on the latest medical evidence – not wellness myths.

Book an appointment | Find your nearest clinic